Open Label Study of Octreotide Implant in Patients With Acromegaly
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) response of a hydrated and
non-hydrated 84 mg octreotide implant in patients with acromegaly in the first 6 weeks of
treatment.